Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Regulatory Approval

Every regulatory approval filing by a US-listed company that our alert engine sent, newest first.

9:25 AM ET 8-K
Regulatory Approval Edesa Biotech, Inc. EDSA

Edesa Biotech Regulatory Approval

Edesa Biotech announced that the European Commission has granted orphan designation to its investigational drug paridiprubart for the treatment of Acute Respiratory Distress Syndrome (ARDS). The designation provides regulatory incentives including reduced development fees and potential market exclusivity for up to 10 years following approval.

Counterparty
European Commission
Term
10 years
9:19 AM ET 8-K
Regulatory Approval MiniMed Group, Inc. MMED

MiniMed Group Regulatory Approval

MiniMed Group received FDA clearance for its MiniMed Fit™ patch pump, the company's first tubeless insulin pump, several months ahead of schedule. The approval triggers a $162 million one-time R&D payment obligation and has led the company to accelerate its U.S. commercial launch to Spring 2027.

8:36 AM ET 8-K
Regulatory Approval Tandem Diabetes Care Inc TNDM

Tandem Diabetes Care Regulatory Approval

Tandem Diabetes Care received FDA 510(k) clearance for Tandem Mobi, the world's first and only tubeless automated insulin delivery system with up to 7 days of wear. The clearance allows the pump to offer both tubed and tubeless infusion options, with a full commercial launch planned for the first half of 2027.

4:46 PM ET 8-K
Regulatory Approval InspireMD, Inc. NSPR

InspireMD Regulatory Approval

InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. This approval doubles the company's total addressable market in the U.S., providing access to over 35,000 annual procedures with its proprietary MicroNet technology.

4:08 PM ET 8-K
Regulatory Approval Metagenomi Therapeutics, Inc. MGX

Metagenomi Therapeutics Regulatory Approval

Metagenomi Therapeutics received FDA clearance for its Investigational New Drug (IND) application for MGX-001, its lead program for the treatment of hemophilia A. This milestone enables the company to initiate the INTEGR8 Phase 1/2 first-in-human clinical trial in the first half of 2027. The company also reported Q3 2026 financial results with $101.7 million in cash to support operations into 2028.

“We are thrilled to reach this pivotal milestone with the FDA clearance of our IND for MGX-001, our lead, wholly owned program in hemophilia A. MGX-001 is designed to leverage our proprietary genome editing platform to integrate a Factor VIII (FVIII) gene site-specifically into the genome, harnessing the power of the body’s native albumin promoter to drive durable, endogenous FVIII production.”

Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.